Parkman Healthcare Partners’s Harvard Bioscience HBIO Stock Holding History

Parkman Healthcare Partners’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-30,535	Closed	-$782K	–	88
2022 Q3	$782K	Sell	30,535 -4,640	-13%	-$154K	0.22%	78
2022 Q2	$1.27M	Sell	35,175 -28,208	-45%	-$1.27M	0.47%	54
2022 Q1	$3.94M	Buy	63,383 +9,675	+18%	+$572K	1.15%	33
2021 Q4	$3.79M	Buy	53,708 +6,171	+13%	+$439K	0.84%	37
2021 Q3	$3.32M	Buy	47,537 +7,300	+18%	+$581K	0.84%	35
2021 Q2	$3.35M	Buy	+40,237	New	+$2.85M	0.73%	45

Other funds holding HBIO

272 Capital Dallas, Texas $40M AUM 150.07% 1-Year Est. Return

Harvey Partners Tarrytown, New York $1.26B AUM 64.44% 1-Year Est. Return

PAIM

Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return

AMH Equity Great Neck, New York $80.3M AUM 78.34% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

ACM

Archon Capital Management Seattle, Washington $177M AUM 108.05% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MIM

Meros Investment Management Dallas, Texas $231M AUM 35.94% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

Parkman Healthcare Partners's HBIO Position: Q4 2022 in Review

Parkman Healthcare Partners sold out of Harvard Bioscience (HBIO) in Q4 2022, closing a stake of 30,535 shares — an estimated $782K sold.

Parkman Healthcare Partners first reported a position in HBIO in Q2 2021 and held it in 6 quarters. The position peaked at $3.94M in Q1 2022. 68 funds tracked by Wall St. Rank hold HBIO as of Q4 2022.

Parkman Healthcare Partners reported no remaining Harvard Bioscience position as of Q4 2022 after selling out during the quarter.
Parkman Healthcare Partners sold 30,535 Harvard Bioscience shares in Q4 2022, an estimated $782K.
Parkman Healthcare Partners first reported a position in Harvard Bioscience in Q2 2021 and held it in 6 quarters.
Parkman Healthcare Partners's Harvard Bioscience position peaked at $3.94M in Q1 2022.
68 funds tracked by Wall St. Rank held Harvard Bioscience as of Q4 2022.

Based on Parkman Healthcare Partners's 13F filing for Q4 2022, filed 13 Feb 2023.